Remarkably, when the ATG12-shRNA/JIMT1 xenografts weretreated with trastuzumab weekly, the mean tumor size was drastically reduced to 46±21mm3, thus demonstrating that the sensitivity of trastuzumab-refractory JIMT1 xenograftsto trastuzumab increased dramatically when the cells were depleted of the autophagy driver ATG12.Whereas trastuzumab treatment reduced the tumor volume of ATG12-expressing JIMT1 xenografts 63 dayspost-injection by approximately 30%, trastuzumab exposure reduced the tumor volume of ATG12-silencedJIMT1 xenografts by an impressive 98% over the same treatment time (Fig. 5). The gene discussed is ATG12; the disease is neoplasm.